October 16, 2024
Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.
October 16, 2024
Supported by Otsuka, new research calculated the value of daily hours spent on basic chores and complex tasks required to support a loved one with AD.
October 15, 2024
Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.
October 15, 2024
A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.
October 15, 2024
Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals.
October 14, 2024
The group of women least likely to return for a regular preventive screening mammogram after a false positive result surprised this primary investigator.
October 14, 2024
Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.
October 11, 2024
The elinzanetant NDA is based on data, including long-term efficacy, from the OASIS phase 3 clinical trial program, according to Bayer.
October 11, 2024
After a false positive outcome on screening mammography, a short interval call back for repeat imaging was a significant deterrent to future screening.
October 11, 2024
CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.